Skip to content

SARS Cov-2 in Conjunctival Secretion in COVID-19 Patients

SARS Cov-2 in Conjunctival Secretions in an Italian Lombardia Cohort of Patients

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04402853
Enrollment
100
Registered
2020-05-27
Start date
2020-02-01
Completion date
2020-05-20
Last updated
2020-12-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sars-CoV2, Tear

Keywords

COVID 19, EYE, Tears

Brief summary

Observational study to evaluate the presence of SARS COV-2 in tears collected in COVID-19 patients in Lombardia region, northern Italy, and to correlate virus presence to concomitant systemic clinical conditions.

Detailed description

Since February 2020, Coronavirurus Disease 2019 associated to a severe acute respiratory syndrome started in China and rapidly spread all over the world and in particular in northern Italy. There are many reasons to justify this rapid diffusion in Italian Lombardia region as the high population density with more possibilities of interpersonal contact, high prevalence of respiratory pathologies, in particular in elderly people, due to pollution, high number of contacts with Chinese population for travelling and business reasons, and at last the non-windy temperate climate conditions, that increases the persistence of virus in the environment. At now, more than eighty thousand citizens from Lombardia Region have been officially affected by the disease with a high death toll, also considering that actual numbers are certainly much underestimated. The aim of the present study was to evaluate the prevalence of SARS COV-2 virus in tears collected from COVID-19 patients by rtPCR analysis directed to target sites of viral RNA, and to correlate virus presence to concomitant systemic clinical conditions

Interventions

DIAGNOSTIC_TESTTears swab

rtPCR on tears swabs samples

Sponsors

Università degli Studi dell'Insubria
Lead SponsorOTHER

Study design

Observational model
CASE_CROSSOVER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Hospitalized COVID 19 patients

Exclusion criteria

* Patients with respiratory support that interferes with tears sampling

Design outcomes

Primary

MeasureTime frameDescription
Virus presence in COVID 19 patients tears1 dayprevalence of SARS CoV 2 virus on tears

Secondary

MeasureTime frameDescription
Concordance to Naso-Pharingeal Swab1 dayEvaluation of concordance with Naso-Pharingeal testing

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026